论文部分内容阅读
olaratumab为一全人源化IgG1单克隆抗体,可选择性与血小板源性生长因子受体α(PDGFR-α)结合,阻断血小板源性生长因子(PDGF)与PDGFR结合,从而抑制PDGFR-α的活性,干扰受体的信号传导系统.olaratumab于2016年10月被美国食品和药物管理局批准联合多柔比星用于治疗成人软组织肉瘤.olaratumab最常见的不良反应表现为恶心、疲劳、肌肉骨骼疼痛、头痛、腹痛、黏膜炎及脱发等.“,”Olaratumab is a fully human IgG1 monoclonal antibody. Olaratumab acts by selectively binding human platelet derived growth factor receptor (PDGFR) α, blocking PDGF ligand binding, inhibiting PDGFR-α activation and disrupting signalling through the receptor. It was approved by the U. S. Food and Drug Administration for use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma in October 2016. The most common adverse reactions of olaratumab are nausea, fatigue, musculoskeletal pain, abdominal pain, headache, mucositis, diarrhea, alopecia and so on.